Caricamento...
Adverse Events Associated with Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization
OBJECTIVES: Radionuclide radium-223 improves survival in men with metastatic castrate-resistant prostate cancer (mCRPC). The FDA Adverse Events Reporting System (FAERS) is a post-market pharmacovigilance database valuable for adverse event (AE) assessments. We analyzed FAERS to identify disproportio...
Salvato in:
| Pubblicato in: | Clin Genitourin Cancer |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7272257/ https://ncbi.nlm.nih.gov/pubmed/31902714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2019.11.017 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|